Flarex®
Fluorometholone acetate 0.1% · ophthalmic suspension
Steroid
Approved uses
Steroid-responsive inflammation of the conjunctiva, cornea, and anterior segment
1 to 2 drops QID; may be increased to 2 drops every 2 hours during the initial 24 to 48 hours
Contraindications
- Acute superficial herpes simplex keratitis, vaccinia, varicella and most other viral diseases of the cornea and conjunctiva.
- Mycobacterial ocular infection.
- Fungal diseases.
- Acute purulent untreated infections.
- Known hypersensitivity to any component of the preparation.
0.1% suspension, 5 mL fill in an 8 mL bottle.
Corticosteroid; suppresses the inflammatory response to inciting agents of mechanical, chemical, or immunologic nature. Raises IOP in susceptible individuals; no generally accepted explanation of this anti-inflammatory property has been advanced.
Warnings & Precautions
- For topical ophthalmic use only: Not for injection.
- Glaucoma and cataract: Prolonged use may result in glaucoma, damage to the optic nerve, defect in visual acuity and visual field, and cataract formation, and may aid in the establishment of secondary ocular infections from pathogens due to suppression of host response.
- Intraocular pressure rise: Corticosteroids cause a rise in intraocular pressure in susceptible individuals; in a small study the average time to a rise was longer than with dexamethasone phosphate, but the ultimate magnitude of the rise was equivalent, and a small percentage of individuals had a significant rise within three days; it is advisable that the intraocular pressure be checked frequently.
- Herpes simplex infection: Treatment requires great caution.
- Acute purulent infection: May be masked or exacerbated by the presence of steroid.
- Corneal wound healing: May be slowed by topical ophthalmic corticosteroids.
- Perforation: In diseases causing thinning of the cornea or sclera, perforation has been known to occur with chronic use of topical steroids.
- Fungal keratitis: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application; consider fungal invasion in any persistent corneal ulceration where a steroid has been or is in use.
- Absorption by soft contact lenses: The preservative benzalkonium chloride 0.01% may be absorbed by soft contact lenses; remove lenses during instillation, and they may be reinserted 15 minutes after instillation.
- Temporarily blurred vision: Vision may be temporarily blurred following dosing; care should be exercised in operating machinery or driving a motor vehicle.
- Contamination: Do not touch the dropper tip to any surface, as this may contaminate the suspension.
Common Side Effects
Glaucoma with optic nerve damage, visual acuity and visual field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur; the label assigns no frequencies. Dysgeusia has been identified in postmarketing use; its frequency cannot be estimated from spontaneous reports.
Pregnancy: Embryocidal and teratogenic in rabbits at low multiples of the human ocular dose, with dose-related fetal loss, cleft palate, deformed rib cage, anomalous limbs, encephalocele, craniorachischisis, and spina bifida after ocular dosing on gestation days 6 to 18; no adequate and well controlled studies in pregnant women, and whether it can cause fetal harm is not known; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth or interfere with endogenous corticosteroid production; whether topical ocular dosing yields detectable milk levels is unknown; use with caution.
Safety and effectiveness in pediatric patients not established; no age threshold stated.